Study found anti-VEGF therapy was linked to kidney function decline in patients with diabetic retinopathy or retinal vein ...
Clinical Trials Arena on MSN
MSD’s DME drug could challenge anti-VEGF reign, late-stage study suggests
While remigromig is non-inferior to Lucentis in terms of efficacy, questions around its tolerability remain.
Study found anti-VEGF therapy was linked to kidney function decline in patients with diabetic retinopathy or retinal vein occlusion.
Surrozen Inc. SRZN skyrocketed on Thursday after the company submitted an Investigational New Drug application to the U.S. Food and Drug Administration to evaluate SZN-8141 for treating diabetic ...
OLN324, a VEGF and Ang-2 inhibitor for wet age-related macular degeneration, achieved improvements in anatomy and retinal fluid that were comparable to faricimab, according to a speaker at Clinical ...
In patients with proliferative diabetic retinopathy, treatment with anti–vascular endothelial growth factor (anti-VEGF) may offer a safer alternative to panretinal photocoagulation (PRP), leading to ...
At the 131st Congress of the French Society of Ophthalmology in Paris, France, the role of second-generation intravitreal anti-VEGF injections compared to corticosteroid injections in treating ...
Please provide your email address to receive an email when new articles are posted on . The programs are designed to provide anti-VEGF treatment for patients who are uninsured or underinsured.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results